Xiaoqi Liu

Xiaoqi Liu, CFA, has built a career at the intersection of corporate transactions, business strategy, and venture building in the biopharma industry. He currently leads business development and strategic finance at Degron Therapeutics, where he drives partnerships and fundraising to support pipeline and platform advancement.

Prior to Degron, Xiaoqi led asset acquisitions and in-licensing efforts at Formation Bio, and managed strategic partnerships for the ENHANZE® drug delivery platform at Halozyme. At Gelesis, he oversaw corporate development, strategy, and alliance management, contributing to the company’s growth into a publicly traded entity on the NYSE through multiple significant financing, licensing, and M&A transactions.

Xiaoqi began his career in venture capital and banking, with roles at Canton Venture Capital, Silicon Valley Bank, and Morgan Stanley, where he focused on biopharma equity investments, M&A advisory, valuation, and market research.

He holds a master’s degree in biotechnology from Northwestern University and a bachelor’s degree from Beijing Normal University, and is a CFA® charterholder.